Non-18F-Fluorodeoxyglucos PET Tracers in Pediatric Disease

Xuezhu Wang; Li Huo

doi:10.1016/j.cpet.2020.03.013

Non-¹⁸F-Fluorodeoxyglucos PET Tracers in Pediatric Disease

PET Clin. 2020 Jul;15(3):241-251. doi: 10.1016/j.cpet.2020.03.013.

Authors

Xuezhu Wang¹, Li Huo²

Affiliations

¹ Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
² Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China. Electronic address: Huoli@pumch.cn.

PMID: 32498980
DOI: 10.1016/j.cpet.2020.03.013

Abstract

¹⁸F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) is an efficient method of diagnosing, staging, treatment evaluation, and recurrence monitoring of pediatric diseases. FDG has some limitations, but other PET/CT tracers have shown promising roles in evaluation of pathologies in pediatric patients. FDG is the most commonly used PET tracer but can accumulate in different types of infection and inflammation. In recent years, more non-FDG tracers have shown utility in evaluating pediatric disease. This article reviews currently available literature on the clinical application of non-FDG PET tracers in the application in the pediatric population.

Keywords: New tracer; PET; Pediatric disease.

Publication types

Review

MeSH terms

Child
Congenital Hyperinsulinism / diagnostic imaging*
Diabetes Mellitus, Type 1 / diagnostic imaging*
Fluorodeoxyglucose F18
Humans
Neoplasms / diagnostic imaging*
Positron-Emission Tomography / methods*
Radiopharmaceuticals*
Sensitivity and Specificity
Urologic Diseases / diagnostic imaging*

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18